RE:FROM F6 Thanks Jkj and F6 re zenith trial.
So since this (zen3694) is the lead drug at this stage it could lead to an IPO in late 2018 IMHO.
However, if I remember correctly this not a double blind trial, and, as I understand it, the patients will be monitored and assessed regularly. This should give an ongoing indication as to the efficacy and safety of zen3694. So if these very sick patients keep living and if the chemical analysis indicates it is working as decribed in the update (reducing the resistance to the partner cancer drug) then investors may see value in Zenith and this could lead to an earlier IPO.
Of course the other possibility is that Don actually does do a reverse takeover of an already listed company (sooner than later) on the TSX and/or NASDAQ and then the market would set the value and provide liquidity.
Anyway, the science is moving forward and this information is being presented at conferences so I guess I'll sit back and wait.
The new structure provides for drug development and revenue from RVX (which could be huge in 2021 or so) and Don did say interested parties could cut one cheque or two - one for RVX or a cheque for both Zenith and RVX. Could be interesting.
Just rambling here.
Cheers
Toinv and GLTA